We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Early Androgen Deprivation Beneficial

Jan 1, 2000
Volume: 
9
Issue: 
1
  • Prostate Cancer, Prostate Cancer

ROCHESTER, NY—Starting anti-androgen therapy immediately after
radical prostatectomy, rather than delaying such treatment until
disease progression, improves outcomes in prostate cancer patients
found to be node positive after radical prostatectomy and pelvic
lymphadenopathy, according to results of an ECOG trial.

The study, headed by Edward M. Messing, MD, of the University of
Rochester Medical Center, randomized 100 patients to receive either
immediate antiandrogen therapy with goserelin (Zoladex), an LHRH
agonist (33 patients) or bilateral orchiectomy (13 patients), or to
be followed until disease progression. Most patients (91) had stage
T2 disease; 7 had stage T1b disease. Two were found to be ineligible.

With a median follow-up of 7.1 years, survival was significantly
better in the immediate-treatment group (P = .02): 18 patients in the
observation group had died, 16 of their prostate cancer, vs 7
patients in the immediate-therapy group, 3 of whom died of their
prostate cancer (N Engl J Med 341:1781-1788, 1999).

Recurrence-free survival was also significantly better in the
immediate-therapy group (P < .001). At the time of last follow-up,
22 observation patients (43%) were alive with no evidence of disease
vs 36 immediate-therapy patients (77%).

“It is unlikely that it will be feasible to repeat our
study,” Dr. Messing said in the report. “Were it to be
carried out today, there would be fewer eligible men because
widespread use of serum PSA testing has led to earlier diagnosis of
prostate cancer.” Dr. Messing noted that the availability of
molecular techniques for identifying nodal micrometastases “may
well increase the relevance of early anti-androgen therapy.”

Related Articles

  • Prostate Cancer Screening in African-American Men
  • No Improved Outcomes in Prostate Cancer With ADT Plus Mitoxantrone/Prednisone
  • No Benefit in Outcomes With Higher Resource Use in Metastatic Prostate Cancer
  • Proton RT for Prostate Cancer Has Reduced Toxicity, Higher Cost vs Other RT Options
  • ‘Screening Smarter’ for Prostate Cancer

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.